Overview
IDRx was a clinical-stage biotechnology company built around precision medicines for gastrointestinal stromal tumors (GIST), a rare cancer. It licensed drug candidates from larger companies and advanced its lead treatment into human studies. GSK completed its acquisition of IDRx in February 2025, while that treatment remained investigational. The deal brought the program into GSK's oncology pipeline; it did not establish that the drug would be approved or commercially successful. [1][2]
Founding Story
IDRx began in 2021. Its co-founders included cancer researcher George Demetri, drug developer Nicholas Lydon, biotech entrepreneurs Alexis Borisy and Robert Forrester, and chief executive Ben Auspitz. The team set out to address a recurring problem in targeted cancer therapy: tumors can develop resistance to an initial drug. [1]
Auspitz led the company at launch; Tim Clackson became CEO in 2024, with Auspitz becoming chair. [10]
The company emerged publicly in August 2022 with $122 million in Series A financing. Andreessen Horowitz and Casdin Capital led the round, with participation from Nextech Invest and Forge Life Science Partners. The a16z account described the company as combining drug candidates from different organizations with an experienced research team. That is an investor's account of its thesis, not proof of clinical success. [3][4]
Timeline
- 2021: IDRx was founded. [1]
- 2022: The company announced its Series A and licenses for IDRX-42 and IDRX-73. [3][4]
- 2023–2024: The first-in-human StrateGIST 1 study tested IDRX-42 in patients with advanced GIST. The company reported preliminary results and raised a $120 million Series B in 2024. [5][6]
- January 2025: GSK agreed to acquire IDRx. [1]
- February 21, 2025: GSK completed the acquisition. [2]
- 2026: GSK continued clinical development of IDRX-42, also called velzatinib. [7][8]
What They Built
IDRx developed experimental small-molecule drugs aimed at proteins that can drive GIST. Many GIST tumors involve changes in the KIT gene. Existing targeted treatments can stop working as tumors develop additional mutations. IDRX-42 was designed to inhibit a range of KIT mutations, including resistance mutations. [1]
The company's starting assets came from licensing. IDRx licensed IDRX-42 from Merck KGaA of Darmstadt, Germany, and IDRX-73 from Blueprint Medicines. These are distinct organizations; Merck KGaA is also distinct from the U.S. company Merck & Co. Rather than discover every asset internally, IDRx assembled programs and concentrated on their clinical development. [4]
In June 2024, IDRx reported preliminary results from the first phase of StrateGIST 1. At the April data cutoff, 73 people had received IDRX-42 and 66 were evaluable for efficacy. The company reported a 23% objective response rate across evaluable patients, whose median was four previous treatment lines. This early, uncontrolled study was designed to assess dose and safety as well as activity; its results do not prove comparative benefit. [5]
Market Position
Target Customers
IDRx designed its lead program for patients with advanced GIST, with clinicians and regulators deciding whether the clinical evidence supports its use. [1]
Market Size
GSK described GIST as a rare soft-tissue sarcoma; IDRx did not disclose a proven commercial market for its investigational treatment. [1]
Competition
IDRx operated in a specialized oncology market where existing drugs, including imatinib and later-line treatments, already served GIST patients. A new treatment needed evidence that it could address an unmet need while maintaining an acceptable safety profile. GSK framed the acquisition around resistance mutations and development in earlier treatment settings. Those were the buyer's goals, not established outcomes. [1][2]
Business Model
IDRx was a development-stage drug company. Its funding supported research, clinical trials, and the work needed to advance candidates toward possible regulatory submissions. The public sources reviewed do not establish product revenue or a commercial launch. Its license for IDRX-42 carried future financial obligations: after the acquisition, GSK assumed responsibility for success-based milestone payments and tiered royalties owed to Merck KGaA. [1][4]
Traction
The $122 million Series A gave IDRx capital and two licensed assets. Its $120 million Series B in August 2024 supported the ongoing StrateGIST 1 study and plans for a pivotal second-line study. Financing and early clinical signals showed investor interest and development progress, but neither demonstrated that the candidate would reach patients as an approved product. [4][6]
Outcome and evolution
A buyer for an investigational program
GSK announced the acquisition in January 2025 and confirmed completion in February. The announced terms were $1 billion upfront and a potential $150 million regulatory approval milestone, plus separate obligations to Merck KGaA. GSK's later financial report stated that the closing payment was $1.1 billion after a working-capital adjustment. The milestone was contingent, not an assured payment. [1][2]
Development after the sale
GSK continued to study the lead candidate after the deal. Its study register lists the first-in-human trial, and a later phase 3 protocol compares IDRX-42 with sunitinib in eligible patients with advanced GIST. A 2026 conference abstract calls the candidate velzatinib. These studies are evidence of continued development, not approval or proof of superiority. [7][8][9]
Key Lessons
- Account for the original owner. IDRx licensed IDRX-42, and GSK assumed milestones and royalties alongside the candidate.
- Separate the deal from the clinical outcome. GSK bought an investigational program; its medical and commercial outcomes still depended on later studies and regulatory decisions.
Sources
- GSK and IDRx acquisition agreement, January 2025
- GSK 2025 financial results, acquisition completion and consideration
- Andreessen Horowitz, investment announcement
- IDRx launch and Series A
- IDRx preliminary phase 1 results, June 2024
- IDRx Series B announcement
- GSK study register, StrateGIST 1
- UK Health Research Authority, phase 3 protocol summary
- Journal of Clinical Oncology, 2026 study abstract
- BioCentury, 2024 leadership changes